stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) Revenue
Relay Therapeutics, Inc.'s revenue for fiscal 2025 was $15.4M, up 53.4% from $10.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $11.0M. Over the past ten years it has ranged from $1.4M (fiscal 2022) to $82.7M (fiscal 2020); the current reading is higher than 67% of that period. Relay Therapeutics, Inc. ranks 210th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $15.4M | 53.44% |
| FY2024 | $10.0M | (60.83%) |
| FY2023 | $25.5M | 1,749.82% |
| FY2022 | $1.4M | (54.41%) |
| FY2021 | $3.0M | (96.34%) |
| FY2020 | $82.7M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $350.0K | (88.33%) |
| Mar 2026 | $3.0M | (57.14%) |
| Dec 2025 | $7.0M | 933.83% |
| Jun 2025 | $677.0K | (91.18%) |
| 15 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $1.2B |
| IOVA Iovance Biotherapeutics, Inc. compare | $379.0M |
| ABCL AbCellera Biologics Inc. compare | $66.2M |
| TNGX Tango Therapeutics, Inc. compare | $62.4M |
| XENE Xenon Pharmaceuticals Inc. compare | $16.9M |
| RLAY Relay Therapeutics, Inc. | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | — |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| IRON Disc Medicine, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RLAY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement